Patient HLA type and antibodies are not used as part of the listing but form part of the immunological risk assessment of any offer. Therefore prior to listing, laboratory tests and other data that would be required include:

• ABO grouping and confirmation
• HLA typing and confirmation
• HLA antibody screening by CDC and Luminex on at least two samples taken not less than 24 hours apart
• Patient demographics, including DOB
• Potential age related co-morbidities
• Patient height and weight
• Patient renal function
• Patient NHS status
• Patient virology, including HIV, EBV, CMV Hepatitis B and C
• Other co-morbidities such as BMI, smoking history, hypertension, vascular disease
• Current or historic malignancy status
• Listing category e.g. Super Urgent, Urgent, Non Urgent
• Once listed, 3 monthly HLA antibody screening by CDC and Luminex